openPR Logo
Press release

Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

11-27-2017 06:44 AM CET | Health & Medicine

Press release from: Plasma Protease C1-inhibitor Treatment

Market Research

Market Research

Researchmoz added Most up-to-date research on "Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025" to its huge collection of research reports.

Global Plasma Protease C1-inhibitor Treatment Market: Overview
This report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large number of acute HAE patients is increasing the usage of plasma protease C1-inhibitors treatment. Increasing prevalence of rare diseases around the world, promising pipeline drugs and novel therapies, rising investments in innovation of inhibitor drugs and increasing HAE awareness programs are the major drivers of the global plasma protease C1-inhibitors treatment market.
The plasma protease C1-inhibitors treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, dosage type, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises Porters Five Forces analysis to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global plasma protease C1-inhibitors treatment market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1363998

Global Plasma Protease C1-inhibitor Treatment Market:
Market SegmentationBased on drug class, the market has been segmented into C1-inhibitors (C1-esterase Inhibitor, Recombinant Inhibitor); Kallikrein Inhibitor (Kalbitor); Selective Bradykinin B2 Receptor Antagonist (Firazyr). The drug class market segments have been analyzed based on available approved products, cost-effectiveness, and preference given by the physicians for the treatment of HAE patients. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Based on distribution channel, the plasma protease C1-inhibitors treatment market has been segmented into four major categories: hospital pharmacies, and independent pharmacies & outlets. The plasma protease C1-inhibitors treatment market is also segmented into dosage type lyophilized and liquid/injectable. The market segments have been extensively analyzed based on prevalence of the diseases, available treatment, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, the global plasma protease C1-inhibitors treatment market has been categorized into four major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (EU-5 Countries, BENELUX Countries, and Rest of Europe), Latin America (Brazil, Argentina, and Rest of Latin America) and Rest of World (Australia, Israel, and Rest of World Countries). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Browse Detail Report With TOC @ https://www.researchmoz.us/plasma-protease-c1inhibitor-treatment-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html/toc

Global Plasma Protease C1-inhibitor Treatment Market: Competitive Landscape
The report also profiles major players in the global plasma protease C1-inhibitors treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Shire plc, CSL Limited, Sanquin and Pharming Group N.V.
The Global Plasma Protease C1-inhibitor Treatment Market is segmented as given below:

Global Plasma Protease C1-inhibitors Treatment Market, by Drug Class
C1-inhibitors
C1-esterase Inhibitor
Recombinant Inhibitor
Kallikrein Inhibitor (Kalbitor)
Selective Bradykinin B2 Receptor Antagonist (Firazyr)

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology

3. Executive Summary : Global Plasma Protease C1-Inhibitor Treatment Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, 2015–2025
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis

5. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Drug Class
5.1. Introduction & Definition
5.2. Key Trends
5.3. Market Forecast By Drug Class, 2015–2025
5.3.1. C1-Inhibitor
5.3.1.1. C1-Esterase Inhibitor
5.3.1.2. Recombinant Inhibitor
5.3.2. Kallikrein Inhibitor (Kalbitor)
5.3.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr)
5.4. Market Attractiveness By Drug Class

6. Global Plasma Protease C1-Inhibitor Treatment Market Analysis and Forecasts, By Dosage Type
6.1. Introduction & Definition
6.2. Market Forecast By Dosage Type, 2015–2025
6.2.1. Lyophilized
6.2.2. Liquid/Injectable
6.3. Market Attractiveness By Dosage Type

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025 here

News-ID: 832739 • Views:

More Releases for Inhibitor

Immune Checkpoint Inhibitor
Immune Checkpoint Inhibitors Market Insights 2019, Global and Chinese Scenario is a professional and indepth study on the current state of the global Immune Checkpoint Inhibitors industry with a focus on the Chinese market. The report provides key statistics on the market status of the Immune Checkpoint Inhibitors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019
Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation. Download the sample Report @ https://www.pharmaproff.com/request-sample/1209 Many studies have demonstrated role of galectins in the pathogenesis of various diseases including
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019
Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation. Download the sample Report @ https://www.pharmaproff.com/request-sample/1209 Many studies have demonstrated role of galectins in the pathogenesis of various diseases including
Neuroendocrine Carcinoma Market: Both tyrosine kinase inhibitor and mTOR inhibit …
Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions in the globe. It has also included an in-depth analysis on the various key players participating in the global neuroendocrine carcinoma market along with key developments taking place during the 2017-2027 timeline. Future Market Insights, in its recent publication titled “Neuroendocrine
Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor o …
"The Report Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Summary Plasminogen Activator Inhibitor 1 (Endothelial Plasminogen Activator Inhibitor or PAI1 or SERPINE1) pipeline Target constitutes close to 10 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report
Cytokine Inhibitor Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Cytokine Inhibitor Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-cytokine-inhibitor-market-research-report-2017-1541209 In this report, the global Cytokine Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions,